With the finding that perturbed exocytosis is common to both C2A and C2B SYT1 variants, and that this correlates with disorder severity, impairments to evoked neurotransmitter release emerge as a core tractable target to investigate for therapeutic amelioration of SYT1-associated neurodevelopmental disorder. Here, SYT1 is linked to neurodevelopmental disorder.